A recent study by Zhuang et al. 33 involving a cohort of 3774 Chinese NSCLC patients reported a lower co-mutation rate of 1.67% in 5 tested driver genes (EGFR, KRAS, ALK, ROS1 and BRAF) while 5% of patients in another cohort of 1,000 NSCLC patients at The NCI’s Lung Cancer Mutation Consortium were reported to harbour concomitant driver gene mutations48. This evidence concerns the gene EGFR and lung carcinoma.